logo
logo
Molecular Partners AG

Molecular Partners AG

NASDAQ•MOLN
CEO: Dr. Patrick Amstutz Ph.D.
セクター: Healthcare
業種: Biotechnology
上場日: 2021-06-16
Molecular Partners AG, a clinical-stage biotechnology company, develops designed ankyrin repeat proteins therapeutics for the treatment of oncology and virology diseases in Switzerland. The company develops MP0317, a CD40 agonist designed to activate immune cells within the tumor microenvironment by anchoring to fibroblast activation protein that is in Phase I clinical trial; and MP0533, a novel tetra-specific T cell-engaging DARPin for acute myeloid leukemia. It also develops Switch-DARPin platform, a multispecific cKIT x CD16a x CD47 Switch-DARPin program for targeted and conditional immune cell activation; and Radio-DARPin Therapy (RDT) platform, a delivery system for effective and selective delivery of radioactive payloads to solid tumors. It has license and research collaboration agreements with Novartis Pharma AG to develop DARPin-conjugated radioligand therapies; and collaboration agreement with Orano Med SAS to develop novel Radio-DARPin therapeutics. Molecular Partners AG was incorporated in 2004 and is headquartered in Schlieren, Switzerland.
連絡先情報
Wagistrasse 14, Schlieren, 8952, Switzerland
41-44-755-77-00
www.molecularpartners.com
時価総額
$177.27M
PER (TTM)
-2.2
34.6
配当利回り
--
52週高値
$5.10
52週安値
$3.36
52週レンジ
79%
順位55Top 80.0%
2.6
F-Score
改良版 Piotroski 分析
10年ファンダメンタル
弱い • 2.6 / 9 ポイント
スコアレンジ (0-9)
8-9: 価値が優れている
6-7: 基礎体質が強い
4-5: 全体的に堅調
0-3: パフォーマンスが弱い
データ期間: 2016-2025

財務ダッシュボード

Q3 2025 データ

売上高

$0.00-100.00%
直近4四半期の推移

EPS

-$0.40-34.69%
直近4四半期の推移

フリーCF

-$12.45M-26.46%
直近4四半期の推移

2024 Annual 決算ハイライト

主なハイライト

Net Loss Narrows Significantly Net loss attributable to shareholders reduced to 54.0 M CHF in 2024 from 62.0 M CHF loss in 2023, showing improved operating results.
Consistent R&D Investment Maintained Research and development expenses remained stable at 48.6 M CHF for 2024, supporting pipeline advancement across oncology programs.
Substantial Cash Reserves Remain Total cash and short-term deposits stood at 149.4 M CHF as of December 31, 2024, funding operations well into 2027.
MP0533 Clinical Data Positive MP0533 Phase 1 trial showed increased response rates in cohort 8; initial data on amended dosing scheme expected in 2025.

リスク要因

Collaboration Revenue Decreased Total revenues dropped to 5.0 M CHF in 2024, down from 7.0 M CHF in 2023, due to Novartis agreement revenue recognition concluding.
Substantial Additional Funding Needed Expect significant expenses to increase; failure to secure capital may force delay, limit, or terminate product development operations.
DARPin Platform Dependency Risks Business heavily dependent on DARPin platform success; base patents expired, creating competitive vulnerability and IP challenges.
Clinical Trials Face Uncertain Outcomes Drug development is lengthy, expensive process; clinical trial delays or negative results could halt regulatory approval and commercialization.

見通し

Advance Radio-DARPin Therapy Pipeline Preparing IND submission for MP0712 (DLL3 RDT) targeting SCLC, aiming for first-in-human trial in first half 2025.
Focus on Oncology Product Candidates Strategy centers on advancing MP0533 (AML/MDS) and MP0317 (solid tumors) using multi-specific and localized activation approaches.
Expand Strategic Partnership Opportunities Will seek collaborations for complementary technology, expanding platform potential beyond core focus areas like oncology.
Increased Compliance Costs Expected Expect increased legal and accounting expenses due to U.S. public company compliance requirements and corporate governance.

同業比較

売上高 (TTM)

Alector, Inc.ALEC
$69.05M
+12.3%
Spero Therapeutics, Inc.SPRO
$35.77M
-64.7%
C4 Therapeutics, Inc.CCCC
$30.11M
-10.6%

粗利益率 (最新四半期)

C4 Therapeutics, Inc.CCCC
100.0%
+13.4pp
Alector, Inc.ALEC
100.0%
+0.0pp
Applied Therapeutics, Inc.APLT
100.0%
+0.0pp

主要指標

銘柄コード
時価総額
PER (TTM)
ROE (TTM)
負債比率
CYBN$413.02M-2.0-54.5%15.9%
PEPG$378.80M-1.9-84.1%9.2%
ALEC$212.84M-1.9-123.0%11.3%

長期トレンド

直近4四半期
売上高
純利益
営業キャッシュフロー
4四半期売上高CAGR
N/M
売上高の変動が大きい
4四半期純利益CAGR
N/M
収益構造の変化
キャッシュフロー安定性
0%
キャッシュフローに注意が必要

深度リサーチ

次回決算:2026年3月5日
|
EPS:-$0.38
|
売上高:-
財務レポート
財務データ
全年度

  • Form 20-F - FY 2024

    会計期末: 2024年12月31日|提出日: 2025年3月6日|
    売上高: $5.65M-29.4%
    |
    EPS: $-1.81+15.9%
    予想を下回る

  • Form 20-F - FY 2023

    会計期末: 2023年12月31日|提出日: 2024年3月14日|
    売上高: $7.83M-96.3%
    |
    EPS: $-2.10-152.1%
    予想を下回る

  • Form 20-F - FY 2022

    会計期末: 2022年12月31日|提出日: 2023年3月9日|
    売上高: $7.83M+1931.7%
    |
    EPS: $-2.10+276.2%
    予想を上回る

  • Form 20-F - FY 2021

    会計期末: 2021年12月31日|提出日: 2022年3月15日|
    売上高: $7.83M-0.1%
    |
    EPS: $-2.10+17.9%
    予想を下回る